Athenex Stock

Athenex Current Assets

Delisted

The Current Assets of Athenex (ATNX) as of Aug 24, 2026 is 117.79 M USD. In the previous year, Current Assets was 61.91 M USD — a change of 90.26% (higher).

Current Assets

117.79 MUSD

YoY

90.26%

Last updated:

Current Assets of Athenex is 2026 117.79 M USD. Current Assets of Athenex was 2025 61.91 M USD. It decreases by 90.26% higher compared to the previous year.

The Athenex Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2015
65.16 M USD
Jan 1, 2016
51.95 M USD
Jan 1, 2017
83.79 M USD
Jan 1, 2018
170.87 M USD
Jan 1, 2019
230.94 M USD
Jan 1, 2020
291.96 M USD
Jan 1, 2021
61.91 M USD
Jan 1, 2022
117.79 M USD
The Athenex Current Assets history
YEARCurrent AssetsYoY
117.79 MUSD+90.26%
61.91 MUSD-78.80%
291.96 MUSD+26.42%
230.94 MUSD+35.16%
170.87 MUSD+103.92%
83.79 MUSD+61.30%
51.95 MUSD-20.28%
65.16 MUSD+21,620.67%
300,000.00USD
Access this data via the Eulerpool API

Athenex Stock analysis

What does Athenex do? Athenex Inc was founded in 2003 and is headquartered in Buffalo, New York. The company specializes in the development and marketing of innovative drugs and therapies for the treatment of cancer and other serious diseases. Athenex's business model is based on collaboration with other companies and research institutions. The company works closely with academic partners to identify and develop new technologies and active ingredients. Athenex has also entered into several collaboration agreements with major pharmaceutical companies to facilitate the marketing of its products. The company has multiple divisions: Athenex Pharmaceutical Division, Athenex Oncology Division, and Athenex Pharmaceutical Technology Division. The Athenex Pharmaceutical Division focuses on the development and marketing of drugs for the treatment of cancer and other serious illnesses. The company has several promising drug candidates in its pipeline, including Oratopo, a drug for the treatment of breast cancer, and KX-2-391, a drug for the treatment of prostate cancer. The Athenex Oncology Division focuses on the development and marketing of innovative cancer treatment methods. The company has several promising therapy approaches in its pipeline, including an immunological cancer treatment based on activating the immune system to fight cancer cells. The Athenex Pharmaceutical Technology Division utilizes advanced technologies to improve the effectiveness and tolerability of drugs, including novel drug delivery systems and innovative packaging forms. Athenex also offers a wide range of products and services for the pharmaceutical industry, including drug development and manufacturing, as well as the supply of active ingredients and excipients. Overall, Athenex has a broad and interesting business model and a promising portfolio of drug candidates and therapy approaches in its pipeline. The company has also established strong partnerships with other companies and research institutions to advance its development and marketing of drugs and therapies. Athenex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athenex stock

Current Assets of Athenex is 117.79 M USD in 2026.

Current Assets of Athenex changed from 61.91 M USD to 117.79 M USD, representing a 90.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Athenex since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Athenex historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Athenex

All Key Metrics — Athenex